A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom
Clinical trial NCT05555979 · COMPLETED
Trial details
- NCT number
- NCT05555979
- Sponsor
- AbbVie
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2022-12-14
- Primary completion
- 2024-04-10
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.